Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2014

01-04-2014 | Original Article

18F-FDG PET/CT impact on testicular tumours clinical management

Authors: Valentina Ambrosini, Giorgia Zucchini, Silvia Nicolini, Annalisa Berselli, Cristina Nanni, Vincenzo Allegri, Andrea Martoni, Rubello Domenico, Antonia Cricca, Stefano Fanti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2014

Login to get access

Abstract

Purpose

Testicular tumour is the most common malignancy in young men. The diagnostic work-up is mainly based on morphological imaging. The aim of our study was to evaluate the clinical impact of 18F-FDG PET/CT in patients with testicular tumour.

Methods

We retrospectively evaluated all patients studied by 18F-FDG PET/CT at our centre. Inclusion criteria were: pathological confirmation of testicular tumour, contrast-enhanced CT scan performed within a month of the PET/CT scan, and clinical/imaging follow-up performed at the Oncology Unit of our hospital. Overall, 56 patients were enrolled and 121 PET/CT scans were evaluated. 18F-FDG PET/CT was performed following standard procedures and the results were compared with clinical, imaging and follow-up data. Clinicians were contacted to enquire whether the PET/CT scan influenced the patient's management. Answers were scored as follows: start/continue chemotherapy or radiotherapy, indication for surgery of secondary lesions, and clinical surveillance.

Results

On a scan basis, 51 seminoma and 70 nonseminoma (NS) cases were reviewed. Of the 121 cases. 32 were found to be true-positive, 74 true-negative, 8 false-positive and 6 false-negative by PET/CT. PET/CT showed good sensitivity and specificity for seminoma lesion detection (92 % and 84 %, respectively), but its sensitivity was lower for NS forms (sensitivity and specificity 77 % and 95 %, respectively). The PET/CT scan influenced the clinical management of 47 of 51 seminomas (in 6 chemotherapy was started/continued, in 3 radiotherapy was started/continued, in 2 surgery of secondary lesions was performed, and in 36 clinical surveillance was considered appropriate), and 59 of 70 NS (in 18 therapy/surgery was started/continued, and in 41 clinical surveillance was considered appropriate).

Conclusion

Our preliminary data demonstrate the potential usefulness of PET/CT for the assessment of patients with testicular tumour. It provides valuable information for the clinical management, particularly for clinical surveillance, post-therapy assessment and when relapse is suspected.
Literature
1.
go back to reference La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60.PubMedCrossRef La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60.PubMedCrossRef
2.
go back to reference Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–36.PubMedCrossRef Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–36.PubMedCrossRef
3.
go back to reference Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp. 2012;36(3):127–45.PubMedCrossRef Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp. 2012;36(3):127–45.PubMedCrossRef
4.
go back to reference Brunereau L, Bruyère F, Linassier C, Baulieu J-L. The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging. 2012;93(4):310–8.PubMedCrossRef Brunereau L, Bruyère F, Linassier C, Baulieu J-L. The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging. 2012;93(4):310–8.PubMedCrossRef
5.
go back to reference Hilton S, Herr HW, Teitcher JB, Begg CB, Castéllino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 1997;169(2):521–5.PubMedCrossRef Hilton S, Herr HW, Teitcher JB, Begg CB, Castéllino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 1997;169(2):521–5.PubMedCrossRef
6.
go back to reference De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World J Urol. 2004;22(1):41–6.PubMedCrossRef De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World J Urol. 2004;22(1):41–6.PubMedCrossRef
8.
go back to reference Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.PubMedCrossRef Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.PubMedCrossRef
9.
go back to reference Jeurkar N, Mamtani R, Vaughn DJ. Granulomatosis and testicular germ cell tumors. Urology. 2012;80(6):1303–6.PubMedCrossRef Jeurkar N, Mamtani R, Vaughn DJ. Granulomatosis and testicular germ cell tumors. Urology. 2012;80(6):1303–6.PubMedCrossRef
10.
go back to reference Kaikani W, Boyle H, Chatte G, de la Roche E, Errihani H, Droz J-P, et al. Sarcoid-like granulomatosis and testicular germ cell tumor: the 'Great Imitator'. Oncology. 2011;81:319–24.PubMedCrossRef Kaikani W, Boyle H, Chatte G, de la Roche E, Errihani H, Droz J-P, et al. Sarcoid-like granulomatosis and testicular germ cell tumor: the 'Great Imitator'. Oncology. 2011;81:319–24.PubMedCrossRef
11.
go back to reference Becherer A, Santis MD, Karanikas G, Szabó M, Bokemeyer C, Dohmen BM, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005;54:284–8.PubMedCrossRef Becherer A, Santis MD, Karanikas G, Szabó M, Bokemeyer C, Dohmen BM, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005;54:284–8.PubMedCrossRef
12.
go back to reference Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology. 2004;64:1202–7.PubMedCrossRef Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology. 2004;64:1202–7.PubMedCrossRef
13.
go back to reference Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.PubMedCrossRef Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26(36):5930–5.PubMedCrossRef
14.
go back to reference Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39:815–22.PubMed Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39:815–22.PubMed
15.
go back to reference Schmoll H-J, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v140–6.PubMedCrossRef Schmoll H-J, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, et al. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v140–6.PubMedCrossRef
16.
go back to reference Lassen U, Daugaard G, Eigtved A, Højgaard L, Damgaard K, Rørth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003;30(3):396–402.PubMedCrossRef Lassen U, Daugaard G, Eigtved A, Højgaard L, Damgaard K, Rørth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003;30(3):396–402.PubMedCrossRef
17.
go back to reference Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996;14(5):1637–41.PubMed Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996;14(5):1637–41.PubMed
18.
go back to reference Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, et al.; NCRI Testis Tumour Clinical Study Group. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25(21):3090–5.PubMedCrossRef Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, et al.; NCRI Testis Tumour Clinical Study Group. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25(21):3090–5.PubMedCrossRef
19.
go back to reference Schmoll H-J, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:147–54.CrossRef Schmoll H-J, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, et al. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:147–54.CrossRef
20.
go back to reference de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19(9):1619–23.PubMedCrossRef de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19(9):1619–23.PubMedCrossRef
Metadata
Title
18F-FDG PET/CT impact on testicular tumours clinical management
Authors
Valentina Ambrosini
Giorgia Zucchini
Silvia Nicolini
Annalisa Berselli
Cristina Nanni
Vincenzo Allegri
Andrea Martoni
Rubello Domenico
Antonia Cricca
Stefano Fanti
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2624-3

Other articles of this Issue 4/2014

European Journal of Nuclear Medicine and Molecular Imaging 4/2014 Go to the issue